Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:AVEO

AVEO Pharmaceuticals (AVEO) Stock Price, News & Analysis

AVEO Pharmaceuticals logo

About AVEO Pharmaceuticals Stock (NASDAQ:AVEO)

Key Stats

Today's Range
$14.99
$15.00
50-Day Range
$14.90
$15.00
52-Week Range
$3.06
$15.00
Volume
247,800 shs
Average Volume
601,442 shs
Market Capitalization
$521.45 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

AVEO Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the advancement of therapeutics for oncology, and other areas of unmet medical need. Its product candidates include Tivozanib, Ficlatuzmab, AV-203, AV-380 and AV-353. The company was founded by Ronald A. DePinho, Lynda Chin, and Kenneth E. Weg on October 19, 2001 and is headquartered in Cambridge, MA.

Receive AVEO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AVEO Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AVEO Stock News Headlines

New Year, New Opportunity! 2 AI Stocks Under $10 Ready to Soar
As we step into 2025, artificial intelligence (AI) stocks continue to dominate headlines, and now is the perfect moment to position yourself for the coming year’s potential. Our latest research has uncovered two must-buy AI stocks currently trading under $10/share – an affordable entry with promising growth potential. These stocks are flying under the radar, but it’s only a matter of time before they gain mainstream attention.
See More Headlines

AVEO Stock Analysis - Frequently Asked Questions

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) issued its earnings results on Monday, November, 8th. The biopharmaceutical company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.36) by $0.06. The biopharmaceutical company earned $15.17 million during the quarter, compared to analysts' expectations of $14.29 million. AVEO Pharmaceuticals had a negative trailing twelve-month return on equity of 81.66% and a negative net margin of 30.79%.

AVEO Pharmaceuticals's stock reverse split on the morning of Thursday, February 20th 2020. The 1-10 reverse split was announced on Wednesday, February 19th 2020. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, February 19th 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that AVEO Pharmaceuticals investors own include Advanced Micro Devices (AMD), Micron Technology (MU), OPKO Health (OPK), Alibaba Group (BABA), Meta Platforms (META), Exelixis (EXEL) and NVIDIA (NVDA).

Company Calendar

Last Earnings
11/08/2021
Today
11/21/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:AVEO
CUSIP
05358810
Employees
114
Year Founded
2001

Profitability

Net Income
$-53,340,000.00
Pretax Margin
-30.79%

Debt

Sales & Book Value

Annual Sales
$42.29 million
Book Value
$1.33 per share

Miscellaneous

Free Float
33,619,000
Market Cap
$521.45 million
Optionable
Optionable
Beta
1.00

Social Links

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

This page (NASDAQ:AVEO) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners